Related Experiment Video
Updated: Apr 25, 2026

Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research
Published on: December 15, 2023
Self-Assembled Quercetin-Mecobalamin Nanoparticles Mitigate Ischemic Stroke Injury via Enhanced Neuroprotection and
Tianhao Zhang1,2,3, Shiwen Fan1,2,3,4, Haipeng Ji1,2,3
1Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
None:
Ischemic stroke is the key cause of increased disability and mortality in society. Quercetin (Qu), a natural compound with neuroprotective effects, shows promise for treating ischemic stroke. However, Qu's hydrophobicity may be an important factor limiting its therapeutic efficacy. Here, a novel quercetin nanodrug (Qu-Me NPs) is constructed by a facile self-assembly with mecobalamin (a FDA-approved drug for peripheral neuropathy), aiming to overcome the hydrophobicity and improve the bioavailability of Qu. Qu-Me NPs exhibits excellent dispersibility, uniform particle size, and stability in physiological media. Qu-Me NPs markedly attenuated infarct size, reduced neuroinflammation, and improved functional recovery at a 1/10 dose of free quercetin in the mouse middle cerebral artery occlusion (MCAO) model. Mechanistically, Qu-Me NPs modulated anti-inflammatory and antioxidative stress pathways, including suppression of microglial M1 polarization by the downregulation of Panx1 and attenuation of pro-inflammatory cytokine production (IL-1β, IL-6). These findings suggest that Qu-Me NPs is a new formulation of Qu, safe, and efficient therapeutic nanodrug for treating MCAO with a ready-to-be-clinically translated potential.

